Market Research Reports Ankylosing Spondylitis Patient Digital Landscape | Page 3

Officer, Oncology, Pfizer Global Product Development. “Results from the EMBRACA trial provide evidence supporting the use of TALZENNA in these patients, and we look forward to working with the European Commission to potentially offer an alternative treatment option to chemotherapy.” Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Ankylosing Spondylitis in these regions, from 2013 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America Purchase this report online with 50 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Ankylosing Spondylitis Market Report 2019” @ https://www.businessindustryreports.com/buy-now/162940/single . About us BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves. Media Contact Business Industry Reports Pune – India [email protected] [phone]